"One of the inquiries we are repeatedly receiving is whether it is to late to file a lawsuit that could be part of this multi-district litigation," said Resource4thePeople. "The answer, in the overwhelming number of cases, is no."
"The federal judge in the case has not issued any order prohibiting additional claims being filed and, in his most recent ruling, found that plaintiffs' lawyers will be granted access to documents they were seeking, which means there will still be additional time before any trial is held."
U.S. District Court Judge David R. Herndon granted the request to victims’ lawyers in the multidistrict litigation seeking access to a case settled by Pradaxa manufacturer Boehringer Ingelheim last year.
Judge Herndon’s ruling against Boehringer Ingelheim involved a $95 million settlement over the company’s marketing campaign to promote Pradaxa.
The current litigation before Herndon involves allegations that Pradaxa can cause serious internal bleeding problems which can lead to heart attacks and brain hemorrhages.*
Herndon has scheduled the first bellwether trials in the Pradaxa litigation to start in August, 2014.
Boehringer Ingelheim has denied the claims that have been filed against them in the Pradaxa litigation, including allegations that the company was negligent by failing to adequately warn health care professionals and patients about bleeding side effects.*
According to allegations in the Pradaxa multi-district litigation, the drug was approved by the FDA in 2010 as an improvement over another blood-thinner, warfarin, for patients vulnerable to atrial fibrillation.
Plaintiffs in the Pradaxa multi-district litigation are claiming that in cases of internal bleeding there is an antidote for war
Copyright©2012 Vocus, Inc.
All rights reserved